Načítá se...
Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain
BACKGROUND: A recent randomized‐withdrawal, active‐ and placebo‐controlled, double‐blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour‐related pain in patients who were opioid naive or dissatisfi...
Uloženo v:
| Vydáno v: | Eur J Pain |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5071659/ https://ncbi.nlm.nih.gov/pubmed/27062079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejp.875 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|